Sutro Biopharma Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sutro Biopharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0494
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sutro Biopharma Inc (Sutro Biopharma), formerly Fundamental Applied Biology Inc, discovers, develops and manufactures novel cancer medicines which include antibody-drug conjugates (ADC’s), bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways. Its pipeline portfolio includes STRO-001, a CD74 ADC for the treatment of multiple myeloma, lymphomas, diffuse large B-cell lymphoma (DLBCL) and Mantle cell lymphoma (MCL); STRO-002, targeting ovarian and endometrial cancer. The company develops its pipeline products through Xpress CF platform, a biochemical protein synthesis system which develops therapeutic proteins and discovers drugs for the treatment and prevention of diseases. Sutro Biopharma owns a manufacturing facility in San Carlos, California. The company works in partnership with various pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates. Sutro Biopharma is headquartered in San Francisco, California, the US.

Sutro Biopharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Sutro Biopharma Raises USD60 Million in Venture Financing 10
SutroVax Raises Funds Through Initial Financing Round 11
Sutro Biopharma Raises US$26 Million In Series D Financing 12
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 14
Partnerships 16
Sutro Biopharma Amends Co-Development Agreement with Celgene 16
Sutro Biopharma Enters into Agreement with University of California, San Francisco 18
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 19
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 20
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 21
Licensing Agreements 22
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 22
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 23
Sutro Biopharma Enters Into Licensing Agreement With Scripps Research Institute For Click Chemistry 24
Equity Offering 25
SutroVax Spins Out from Sutro Biopharma 25
Sutro Biopharma Inc – Key Competitors 26
Sutro Biopharma Inc – Key Employees 27
Sutro Biopharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sutro Biopharma Raises USD60 Million in Venture Financing 10
SutroVax Raises Funds Through Initial Financing Round 11
Sutro Biopharma Raises US$26 Million In Series D Financing 12
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 14
Sutro Biopharma Amends Co-Development Agreement with Celgene 16
Sutro Biopharma Enters into Agreement with University of California, San Francisco 18
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 19
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 20
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 21
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 22
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 23
Sutro Biopharma Enters Into Licensing Agreement With Scripps Research Institute For Click Chemistry 24
SutroVax Spins Out from Sutro Biopharma 25
Sutro Biopharma Inc, Key Competitors 26
Sutro Biopharma Inc, Key Employees 27
Sutro Biopharma Inc, Other Locations 28

List of Figures
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sutro Biopharma Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • ReWalk Robotics Ltd (RWLK):企業の財務・戦略的SWOT分析
    Summary ReWalk Robotics Ltd (ReWalk) is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include ReWalk personal system and ReWalk rehabilita …
  • NeuroScientific Biopharmaceuticals Ltd (NSB):企業の財務・戦略的SWOT分析
    NeuroScientific Biopharmaceuticals Ltd (NSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Vifor Pharma AG-製薬・医療分野:企業M&A・提携分析
    Summary Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for tr …
  • Kikkoman Corp:企業の戦略・SWOT・財務情報
    Kikkoman Corp - Strategy, SWOT and Corporate Finance Report Summary Kikkoman Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Innocoll AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Innocoll AG (Innocoll), formerly Innocoll Holdings Plc is a pharmaceutical company that carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company’s pipeline product Xaracoll, a bupivacaine HC …
  • IXICO Plc (IXI)-製薬・医療分野:企業M&A・提携分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints. The company provides clinical trial services for assessing the safety and efficacy of drugs. Its product portfolio includes web-based platform to transf …
  • Tauron Polska Energia SA:発電所・企業SWOT分析
    Tauron Polska Energia SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • PharmAbcine Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PharmAbcine Inc (PharmAbcine) is a biotechnology company that discovers and develops human therapeutic monoclonal antibodies. The company offers products such as bi-specific MAB and lead MAB products. It provides services such as binding test by ELISA, screening by ELISA, mono-phage Ab seque …
  • Suffolk Construction Company Inc:企業の戦略・SWOT・財務情報
    Suffolk Construction Company Inc - Strategy, SWOT and Corporate Finance Report Summary Suffolk Construction Company Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ProPhotonix Limited (PPIX):企業の財務・戦略的SWOT分析
    ProPhotonix Limited (PPIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • New York Blood Center:製薬・医療:M&Aディール及び事業提携情報
    Summary New York Blood Center (NYBC) is a non-profit healthcare organization that offers blood collection and distribution. The organization's blood products comprise red blood cells, plasma products, platelets, frozen blood and washed products, whole blood and granulocytes. It offers medical servic …
  • NSK Ltd (6471):企業の財務・戦略的SWOT分析
    NSK Ltd (6471) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • OAO Gazprom:企業の戦略・SWOT・財務情報
    OAO Gazprom - Strategy, SWOT and Corporate Finance Report Summary OAO Gazprom - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sharp Corporation:企業の戦略・SWOT・財務情報
    Sharp Corporation - Strategy, SWOT and Corporate Finance Report Summary Sharp Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • L E Pritchitt & Co Ltd. :企業の戦略・SWOT・財務情報
    L E Pritchitt & Co Ltd. - Strategy, SWOT and Corporate Finance Report Summary L E Pritchitt & Co Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Plethora Solutions Holdings Plc:製薬・医療:M&Aディール及び事業提携情報
    Summary Plethora Solutions Holdings plc (Plethora), a subsidiary of Regent Pacific is a pharmaceutical company which develops and markets products for the treatment and management of urological disorders. It focuses on the development of medicines for the treatment of urology and sexual health. The …
  • Archer Ltd (ARCHER):石油・ガス:M&Aディール及び事業提携情報
    Summary Archer Ltd (Archer) is an oilfield services company. It provides drilling services, well integrity and intervention, plug and abandonment and decommissioning. Its drilling and work-over services include platform drilling, land drilling, modular rigs, drilling fluids, solids control, engineer …
  • Laboratorios SALVAT SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios SALVAT SA (SALVAT) is a pharmaceutical company with focus on the development and commercialization of innovative medicines. The company manufactures drugs in various segments such as personal healthcare, digestive / metabolism, urological conditions, ophthalmological diseases, E …
  • Altin Yunus Cesme Turistik Tesisler A.S.
    Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report Summary Altin Yunus Cesme Turistik Tesisler A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆